HOME > COMMENTARY
COMMENTARY
- Top-Notch Talents Needed for Pharma’s Lobbying Activities; Stay Current with Policymaking Moves
January 30, 2017
- Hepatology Society Revises Hep C Treatment Guidelines; Looking to Future Research for Non-Responders to IFN-Free Treatment
December 14, 2016
- Taltz Issue Exposes Forex-Sensitive Nature of Drug Pricing System
November 15, 2016
- Are Biosimilars on Verge of Breakthrough in Japan? Initiatives Underway to Prepare for Full-Scale Entry of Major Biosimilars
October 25, 2016
- Policymakers Face Balancing Act over Opdivo Re-Pricing
October 17, 2016
- Can Wholesalers Bear Distribution Costs amid 90% Discount on Generics?
October 11, 2016
- Can Mid-sized Makers Break Away from Long-Listed Product Model?
August 19, 2016
- MHLW’s Feat to Link Drug Review and Reimbursement Policies Put to Test with “Expensive Drugs”
June 28, 2016
- 7 Drugs Picked for Cost-Effective Assessments, but Now How Will They Be Re-Priced Exactly?
May 27, 2016
- Data Corroborate Harshness of Z2 Rule, Only Handful to Escape 2nd Consecutive Application
March 31, 2016
- Global Pharmas Casting Colder Eyes on Japan Market; PhRMA, EFPIA to Up Lobbying Efforts with Govt, Ruling Parties
March 11, 2016
- Companies Can “Veto” Humanitarian Trials for Legitimate Reasons; Cooperation Is Essential, but Access Scheme Shouldn’t Stymie Main Development
February 23, 2016
- It’s Time to Squarely Discuss Proposed Penalty through Drug Price Cuts
February 3, 2016
- Generic Industry’s Tactic to Thwart 50% Pricing Rule Draws Mixed Reviews
January 18, 2016
- Is 7.8% Drug Cost Cut Justifiable? Make “Huge Seller” Re-Pricing a Starter to Discuss This
January 12, 2016
- High Hopes for New Osteoporosis Drugs, but “Treatment Gap” Needs to Be Addressed
November 27, 2015
- Sakigake Designation System to Link Regulatory and Drug Pricing Systems; Could Result in Tougher Scrutiny for Designated Products
November 6, 2015
- Data from Humanitarian Trials to Be Used in Product Reviews; Effective Use of Safety-Related Information Will Be Key
October 13, 2015
- Japan, US, EU Regulators Trod Different Paths to Iressa Approval; Japan’s Capabilities to Be Tested with Sakigake System
September 24, 2015
- How Will Industry Counter Proposed Re-Pricing of “Huge Seller” Drugs?
August 18, 2015
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…